GemVax Obtains Patent Rights Related to Alzheimer's Disease Treatment
[Asia Economy Reporter Ji Yeon-jin] GemVax announced on the 16th that it has acquired a patent for a peptide and a composition containing it, which have the efficacy of preventing and regenerating nerve cell loss.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The patent is for a composition containing a peptide derived from telomerase, which shows preventive and therapeutic effects on nerve cell damage and non-regenerative diseases, including Alzheimer's disease, and is expected to provide a new treatment method for nerve cell damage and non-regenerative diseases.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
